WO2022267086A1 - 一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物及其制备方法和应用 - Google Patents

一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物及其制备方法和应用 Download PDF

Info

Publication number
WO2022267086A1
WO2022267086A1 PCT/CN2021/103464 CN2021103464W WO2022267086A1 WO 2022267086 A1 WO2022267086 A1 WO 2022267086A1 CN 2021103464 W CN2021103464 W CN 2021103464W WO 2022267086 A1 WO2022267086 A1 WO 2022267086A1
Authority
WO
WIPO (PCT)
Prior art keywords
mrna
medicine
uricase
preparation
mrna encoding
Prior art date
Application number
PCT/CN2021/103464
Other languages
English (en)
French (fr)
Inventor
胡勇
Original Assignee
深圳市瑞吉生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市瑞吉生物科技有限公司 filed Critical 深圳市瑞吉生物科技有限公司
Publication of WO2022267086A1 publication Critical patent/WO2022267086A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase

Definitions

  • the present invention requires the priority of the Chinese patent application submitted to the China Patent Office on June 25, 2021, with the application number 202110707208.7, and the title of the invention is "a drug for treating hyperuricemia or gout based on mRNA dosage form and its preparation method" rights, the entire contents of which are incorporated in this application by reference.
  • the invention belongs to the technical field of treating hyperuricemia or gout, and in particular relates to a medicine in mRNA dosage form for treating hyperuricemia, gout or renal function damage, and a preparation method and application thereof.
  • the current standard prevention or treatment regimens for hyperuricemia are treatment with allopurinol, urine alkalinization, water diuresis, and osmotic diuresis.
  • Allopurinol blocks uric acid formation by inhibiting xanthine oxidase, but increases the burden of renal excretion of uric acid precursors (hypoxanthine and xanthine).
  • hypoxanthine xanthine is less soluble in urine than uric acid.
  • Xanthine nephropathy and calculi sometimes occur in patients treated with allopurinol.
  • treatment with allopurinol was ineffective for the excretion of uric acid remaining in the patient's body.
  • Another treatment method is to use the protein drug uricase, which is relatively safe and does not affect the liver and kidney functions of the patient. It is an ideal drug for the treatment of gout.
  • the main adverse event of uricase is infusion reaction, which occurs in up to 40% of patients and occurs before the onset of uric acid lowering with symptoms of nausea, skin flushing, and dyspnea.
  • High titers of antibodies are present in more than 40% of patients and are associated with loss of response to therapy and increased risk of infusion reactions. Some patients using this drug will have severe allergic reactions, and it will appear within 2 hours of using this drug.
  • the object of the present invention is to provide a medicine for the treatment of hyperuricemia, gout or renal dysfunction in mRNA dosage form and its preparation method and application;
  • the medicine for the treatment of hyperuricemia is the mRNA encoding uricase
  • the present invention delivers mRNA encoding uricase to the body, utilizes human cells to express uricase, speeds up the metabolic rate of uric acid in the blood, significantly reduces the uric acid content, and thus plays the role of treating hyperuricemia and gout.
  • the drug for treating hyperuricemia provided by the invention-mRNA encoding uricase has high bioavailability, long half-life, low immunogenicity, greatly reduces allergic reactions, and improves medication compliance and safety of patients.
  • the present invention provides a drug in the form of mRNA for treating hyperuricemia, gout or renal function damage, including the mRNA encoding uricase shown in SEQ ID No.1 and/or SEQ ID No.2.
  • the 5' end of the mRNA encoding uricase is connected to a 5' UTR and a cap structure; the 3' end of the mRNA encoding uricase is connected to a 3' UTR and a poly A tail.
  • the drug is a liquid preparation.
  • the drug is an injection preparation.
  • the concentration of the mRNA encoding uricase in the drug is 0.5-1.5 ⁇ g/ ⁇ l.
  • the solvent of the medicine is physiological saline.
  • the invention provides the preparation method of described medicine, comprises the following steps:
  • RNA in vitro synthesis system including the DNA template to synthesize mRNA in vitro to obtain the mRNA encoding uricase.
  • the RNA in vitro synthesis system includes the following components in terms of 1600 ⁇ l:
  • the procedure for in vitro synthesis of the RNA is 36-38° C. for 5-7 hours.
  • step 3) after obtaining the mRNA encoding uricase further includes: adjusting the concentration of the mRNA encoding uricase and then subpackaging.
  • the invention provides the application of the medicine in the treatment of hyperuricemia, gout or renal function damage.
  • the method of using the drug includes intravenous injection.
  • the medicine for treating hyperuricemia, gout or renal function damage provided by the present invention is the mRNA encoding uricase, and the present invention delivers the mRNA encoding uricase to the body, and uses human cells to express uricase to accelerate It improves the metabolic rate of uric acid in the blood and significantly reduces the content of uric acid, thus playing a role in the treatment of hyperuricemia, gout and renal damage caused by excessive uric acid crystal formation.
  • the drug for treating hyperuricemia provided by the invention-mRNA encoding uricase has high bioavailability, long half-life, low immunogenicity, greatly reduces allergic reactions, and improves medication compliance and safety of patients.
  • the expression levels of TNF ⁇ and IL-8 are far lower than those injected with corresponding protein drugs, indicating that the mRNA encoding uricase provided by the present invention has The immunogenicity is far less than that of corresponding protein drugs.
  • the uric acid level of the rat is not significantly reduced, and the uric acid level in the rat body injected with the mRNA drug encoding uricase provided by the present invention is significantly reduced, indicating that the drug for the treatment of hyperuricemia provided by the present invention The treatment works better.
  • Fig. 1 is the structural representation of the mRNA of encoding uricase
  • Fig. 2 is the plasmid map of pRhe plasmid
  • Fig. 3 is the 36h protein expression level after the mRNA (Seq1 and Seq2) transfection cell of encoding uricase;
  • Figure 4 is the detection of immune factor levels in rats injected with mRNA encoding uricase and corresponding protein drugs, wherein A is the expression level of TNF ⁇ , and B is the expression level of IL-8;
  • Fig. 5 is the level of uric acid in the blood of rats injected with mRNA encoding uricase and corresponding protein drugs;
  • Figure 6 is a comparison of the bioavailability and half-life of uricase mRNA drugs and protein drugs, wherein A is the level of uric acid in blood 7 days after injection of the mRNA (Seq1) encoding uricase and the corresponding protein drug, and B is the injection of mRNA encoding uricase ( Seq2) and the level of uric acid in the blood 7 days after the corresponding protein drug.
  • A is the level of uric acid in blood 7 days after injection of the mRNA (Seq1) encoding uricase and the corresponding protein drug
  • B is the injection of mRNA encoding uricase ( Seq2) and the level of uric acid in the blood 7 days after the corresponding protein drug.
  • the present invention provides a medicine for treating hyperuricemia, gout or renal impairment based on an mRNA dosage form, comprising mRNA encoding uricase shown in SEQ ID No.1 and/or SEQ ID No.2; details are as follows:
  • SEQ ID No.1 (hereinafter referred to as seq 1):
  • SEQ ID No.2 (hereinafter referred to as seq 2):
  • the 5' end of the mRNA encoding uricase is connected to a 5' UTR and a cap structure; the 3' end of the mRNA encoding uricase is connected to a 3' UTR and a poly A tail; the specific results are shown in Figure 1 shown.
  • the medicine for treating hyperuricemia, gout or renal function injury is preferably a liquid preparation, more preferably an injection preparation.
  • the concentration of the mRNA encoding uricase in the pharmaceutical preparation is preferably 0.5-1.5 ⁇ g/ ⁇ l, more preferably 1 ⁇ g/ ⁇ l.
  • the solvent of the mRNA encoding uricase is preferably physiological saline.
  • the preparation method of the physiological saline is not particularly limited in the present invention, and conventional physiological saline in the field can be used.
  • the preparation method of the injection preparation is not particularly limited in the present invention, as long as it meets the requirements of conventional injection preparations in the field.
  • the present invention also provides the preparation method of the medicine, comprising the following steps: 1) synthesizing and transcribing the DNA fragment of the mRNA encoding uricase, cloning the DNA fragment into an expression plasmid to obtain a recombinant plasmid; 2) converting the Transfer the recombinant plasmid into the host cell to obtain the recombinant cell, extract the plasmid from the expanded recombinant cell, and use the extracted plasmid as a template to perform PCR amplification to obtain a DNA template for in vitro expression of mRNA; 3) construct a DNA template comprising the DNA template
  • the RNA in vitro synthesis system performs in vitro synthesis of mRNA to obtain the mRNA encoding uricase.
  • a DNA fragment for transcribing the mRNA encoding uricase is synthesized, and the DNA fragment is cloned into an expression plasmid to obtain a recombinant plasmid.
  • the method for synthesizing the DNA fragment corresponding to the mRNA encoding uricase is not particularly limited, and conventional DNA synthesis methods in the field can be used. In the specific implementation process of the present invention, it is preferred to entrust a biotechnology company to synthesize.
  • the specific sequence of the DNA fragment is determined according to the principle of complementary base pairing.
  • the expression plasmid is preferably a pRhe plasmid.
  • the plasmid map of the pRhe plasmid is shown in FIG. 2 .
  • the DNA fragment is preferably cloned into an expression plasmid by enzyme digestion and ligation; in the present invention, the DNA fragment is preferably double-digested by BamHI and NheI enzymes to obtain an enzyme-cleaved NDA fragment; The expression plasmid is preferably double-digested by BamHI and NheI enzymes to obtain a restriction plasmid; then the restriction DNA fragment and restriction plasmid are connected to obtain a recombinant plasmid.
  • there is no special limitation on the specific operation of the double enzyme digestion and connection and the conventional double enzyme digestion and connection operations in the field can be used.
  • the recombinant plasmid is transferred into a host cell to obtain a recombinant cell, the plasmid is extracted from the multiplied recombinant cell, and the extracted plasmid is used as a template for PCR amplification to obtain in vitro expressed mRNA. DNA template.
  • the host cells are preferably Escherichia coli competent cells; the present invention has no special limitation on the transfer method, and conventional transfer methods in the art can be used.
  • screening of positive recombinant cells and colony sequencing are preferably performed.
  • the screening of the positive recombinant cells is preferably carried out on amp-resistant solid medium.
  • the colony PCR is carried out by selecting the single colony cultured bacterial solution on the amp-resistant solid medium, and the colonies containing the target band in the colony PCR result are selected for sequencing.
  • the sequence of the primer F of the colony PCR is as follows: CTCTAGAGGATCGAACCCTT (SEQ ID No.3); the sequence of the primer R of the colony PCR is as follows: AAACCCGCTGATCAGCCTCG (SEQ ID No.4).
  • the colony PCR amplification program is preferably as follows: pre-denaturation at 98°C for 3min; denaturation at 98°C for 10s, annealing at 60°C for 5s, extension at 72°C for 2min, 34 cycles; final extension at 72°C for 10min.
  • the preferred system of the colony PCR is as follows:
  • the initial concentration of the primer F and the primer R is preferably 10 ⁇ mol/L, and the concentration of the DNA template is preferably 1 ng/ ⁇ l.
  • the colony containing the target band is preferably determined by agarose gel electrophoresis, and then sequenced for verification.
  • the plasmid of the recombinant cell with correct sequencing is extracted; the method for extracting the plasmid is not particularly limited in the present invention, and a plasmid extraction kit is preferably used.
  • the extracted plasmid is used as a template to carry out PCR amplification to obtain a DNA template for expressing mRNA in vitro.
  • the PCR amplification system is preferably as follows in 50 ⁇ l:
  • the initial concentration of the primer F and the primer R is preferably 10 ⁇ mol/L; the concentration of the DNA template is preferably 1 ng/ ⁇ l.
  • the sequence of the primer F is as follows: CTCTAGAGGATCGAACCCTT (SEQ ID No. 3); the sequence of the primer R is as follows: AAACCCGCTGATCAGCCTCG (SEQ ID No. 4).
  • the PrimeSTAR Max Premix (2 ⁇ ) includes the following components: PrimeSTAR Max DNA Polymerase, dNTPs and Mg 2+ .
  • the PCR amplification program is preferably as follows: pre-denaturation at 98°C for 3min; denaturation at 98°C for 10s, annealing at 60°C for 5s, extension at 72°C for 2min, 34 cycles; final extension at 72°C for 10min.
  • the amplified product is preferably detected by agarose gel electrophoresis to determine whether the reaction is successful; the parameters detected by the agarose gel electrophoresis are preferably as follows: 1.5% agar Sugar, 5V/min, 40min. In the present invention, the reaction is considered successful when the target band appears in the agarose gel electrophoresis.
  • the amplification product is preferably concentrated and purified.
  • the concentration is preferably carried out using Millipore 30Kd ultrafiltration tube; the purification is preferably carried out by FPLC; the present invention preferably uses NanoDrop to detect the concentration of the purified template after the purification, and 260/280, When 260/280 is between 1.6 and 1.8, the template is considered qualified.
  • an RNA in vitro synthesis system including the DNA template is constructed to synthesize mRNA in vitro to obtain the active ingredient mRNA.
  • the RNA synthesis system in vitro includes the following components in terms of 1600 ⁇ l:
  • the Enzyme Mix includes T7 RNA polymerase, RNase inhibitor and inorganic pyrophosphatase.
  • the procedure for RNA synthesis in vitro is preferably 36-38°C for 5-7 hours, more preferably 37°C for 6 hours.
  • the RNA synthesis in vitro is preferably carried out in a constant temperature reactor; the RNA synthesis system in vitro is preferably placed in a 2ml RNase-free Tube tube, and multiple tubes are simultaneously reacted at one time; in the RNA synthesis system in vitro The reagents are added in the order of the above components.
  • the present invention preferably further includes the steps of removing DNA template, recovering mRNA and purifying mRNA.
  • the removal of the DNA template is preferably achieved by DNase I digestion; the digestion preferably includes mixing the DNase I with the solution after the RNA in vitro synthesis reaction; the DNase I and the RNA after the in vitro synthesis reaction
  • the volume ratio of the solution is preferably 3:40; the mixing is preferably realized by inverting the RNase-free Tube tube up and down, and the number of inversions is preferably 8 to 12 times, more preferably 10 times.
  • the solution is preferably centrifuged to collect the solution at the bottom of the RNase-free Tube tube.
  • the rotational speed of the centrifugation is preferably 800-1200 rpm, more preferably 1000 rpm; the centrifugation time is preferably 8-12 s, more preferably 10 s.
  • the temperature of the digestion is preferably 37° C.; the time of the digestion is preferably 1 h.
  • the recovery of mRNA is preferably achieved by ammonium acetate solution precipitation; for specific implementation methods, refer to the description in the examples.
  • the quality detection of the mRNA is carried out; the quality detection includes the concentration of the mRNA and the ratio of 260/280 and 260/230 of the mRNA.
  • the range of 260/280 is 1.8-2.1, and the range of 260/230 is greater than 2.0, the mRNA is considered qualified.
  • the purified mRNA is achieved by FPLC purification. After the mRNA is purified according to the present invention, the purified mRNA is preferably subpackaged.
  • Colony PCR steps are as follows:
  • the initial concentration of the primer F and the primer R is 10 ⁇ mol/L; the concentration of the DNA template is 1 ng/ ⁇ l.
  • the sequence of the primer F is as follows: CTCTAGAGGATCGAACCCTT (SEQ ID No.3); the sequence of the primer R is as follows: AAACCCGCTGATCAGCCTCG (SEQ ID No.4).
  • the PCR amplification program is preferably as follows: pre-denaturation at 98°C for 3min; denaturation at 98°C for 10s, annealing at 60°C for 5s, extension at 72°C for 2min, 34 cycles; final extension at 72°C for 10min.
  • the positive clones were judged according to the agarose gel electrophoresis band pattern, the bacteria liquid of the positive clones were expanded and cultured, and the sequencing verification was performed, and the clones with completely correct sequences were selected for the next step.
  • the resulting plasmid was amplified as a DNA template in the following reaction system:
  • Reaction volume 50 ⁇ l (the reaction volume of a single tube, multiple tubes are reacted at the same time)
  • the PCR amplification system is calculated in 50 ⁇ l, preferably as follows:
  • PrimeSTAR Max Premix (2 ⁇ ) includes the following components: PrimeSTAR Max DNA Polymerase, dNTPs and Mg 2+ .
  • the initial concentration of primer F and primer R is preferably 10 ⁇ mol/L; the concentration of the DNA template is preferably 1 ng/ ⁇ l.
  • the sequence of the primer F is as follows: CTCTAGAGGATCGAACCCTT (SEQ ID No. 3); the sequence of the primer R is as follows: AAACCCGCTGATCAGCCTCG (SEQ ID No. 4).
  • the PCR amplification program is as follows: pre-denaturation at 98°C for 3min; denaturation at 98°C for 10s, annealing at 60°C for 5s, extension at 72°C for 2min, 34 cycles; final extension at 72°C for 10min.
  • reaction solution was combined into a 1.5ml Tube tube. 10 ⁇ l was taken for DNA agarose gel electrophoresis detection to confirm the success of the reaction (1.5% agarose, 5 V/min, 40 min).
  • Eligibility criteria a single band appears in the electrophoresis test, and the size is correct.
  • the DNA templates obtained above were concentrated using Millipore 30Kd ultrafiltration tubes.
  • the precipitate was washed with 70% ethanol by volume, centrifuged at 12000 g for 5 min, the supernatant was taken, and dried in the ultra-clean bench for 5 min.
  • NanoDrop to detect the concentration of the purified template and the ratios of 260/280 and 260/230. Samples were taken for DNA agarose gel electrophoresis detection (1.5% agarose, 5V/min, 40min).
  • Eligibility criteria 260/280 between 1.8 and 2.1, 260/230 between 1.6 and 2.2.
  • the DNA template purified by FPLC was concentrated by Millipore 30Kd ultrafiltration tube, and eluted with RNase-free water to dissolve. Use NanoDrop to detect the concentration of the template after ultrafiltration, and the ratios of 260/280 and 260/230. Finally, it was diluted to 150ng/ ⁇ l with RNase-free water.
  • Reaction volume 1600 ⁇ l (placed in a 2ml RNase-free Tube tube, which is the reaction volume of a single tube, multiple tubes can be reacted at the same time).
  • RNA synthesis system in vitro includes the following components in terms of 1600 ⁇ l:
  • RNA synthesis in vitro is 37° C. for 6 hours.
  • the reaction solution was combined into an RNase-free 50ml Tube tube to detect the residual DNA fragments.
  • the three measurement results showed that the residual DNA fragments were 0.013ng, 0.016ng, and 0.017ng per 100 ⁇ g mRNA.
  • Quantitative real-time PCR detection method was adopted, and the specific operation steps were as follows:
  • test solution take an appropriate amount of sample, dilute it 10 times with enzyme-free water, mix well, and mix well.
  • PCR tube loading add 19 ⁇ l qPCR MIX to each well, then add 1 ⁇ l standard curve (ST1/ST2/ST3/ST4/ST5/ST6), ERC, NTC, test solution in turn, and mix well. Three parallels were performed for each sample.
  • the PCR program was set as follows:
  • Calculation formula use the Ct value of the standard to plot the logarithmic value of its concentration, perform linear regression analysis, and substitute the Ct value of the sample into the equation to calculate the "detection value of the concentration logarithm after 10-fold dilution" and calculate "DNA residue”.
  • DNA residual concentration (copies/ ⁇ l) detection value ⁇ dilution factor
  • the Ct difference between the three parallel wells should be less than 1.0; except for samples with a Ct value greater than 35.
  • No-template control NTC should not be detected or greater than 2 Ct values of the lowest concentration of the standard curve.
  • Standard regulations should not be higher than 1ng/ ⁇ l.
  • the recovered mRNA concentration detected by NanoDrop was 5 ⁇ g/ ⁇ l, A260/A280 was 1.90, and A260/A230 was 2.0.
  • the purified mRNA concentration was 2 ⁇ g/ ⁇ l, A260/A280 was 1.95, and A260/A230 was 1.9.
  • Cell preparation Prepare cells for detection 3 days in advance.
  • the 293T cells purchased from the cell bank of the Chinese Academy of Sciences were passaged in cell culture flasks to ensure that the cells were in the logarithmic growth phase when used.
  • Cell dilution Take 1ml of cell suspension, dilute to 5 ⁇ 10 5 cells/ml with DMEM medium containing 10% FBS, and mix by pipetting.
  • the medium was changed 6 hours after transfection, the old medium was sucked off, and each well was replaced with 2 ml of fresh medium (90% DMEM+10% FBS).
  • Coating The concentration of coated standard is 0.1 ⁇ g/ ⁇ l, 0.01 ⁇ g/ ⁇ l, 0.001 ⁇ g/ ⁇ l, 0.0001 ⁇ g/ ⁇ l, 0.00001 ⁇ g/ ⁇ l, 0.000001 ⁇ g/ ⁇ l, diluted in coating buffer, the volume is 100 ⁇ l .
  • the volume of the coated cell lysate was 100 ⁇ l, poured into a 96-well plate, covered with a sealing film, and coated overnight at 4°C.
  • Standard products are recombinant proteins Rasburicase and Pegloticase encoded by mRNA seq1 and mRNA seq2.
  • Plate washing Prepare the eluent, dilute 50x Washing buffer with deionized water, add it to the liquid inlet bottle of the plate washer, set the program, set the volume of each well to 300 ⁇ l, and repeat the wash 4 times.
  • Primary antibody incubation Dilute the primary antibody (1:1000) with dilution buffer, add 100 ⁇ l per well into the washed 96-well plate, and then seal the plate and incubate at room temperature for 1.5 h.
  • Plate washing Complete plate washing according to step 3, and increase the number of plate washing to 6 times.
  • Plate washing Complete plate washing according to step 8. In this step, be sure to wash the plate and dry the solution.
  • Color development Add 100 ⁇ l of TMB buffer, and develop color in the dark for 25 minutes. At this time, the positive sample will appear blue.
  • Termination Add 100 ⁇ l of Stop buffer, read on the microplate within 10 minutes, and set the absorption wavelength to 450nm.
  • Seq1 and Seq2 The mRNAs (Seq1 and Seq2) encoding uricase were transfected into the cells for 30 hours and the protein expression levels are shown in Figure 3 and Table 1. Seq1 mRNA and seq2 have in vitro biological activity and can express the correct protein products in cells. Seq1 mRNA The average expression intensity of Seq2 mRNA is 38.2pg/ml, and the average expression intensity of Seq2 mRNA is 75.1pg/ml.
  • Table 1 Encoding uricase mRNA cell expression level detection (unit: pg/ml)
  • the immunogenicity of the mRNA encoding uricase provided by the present invention is detected, and the evaluation standard is the expression levels of TNF ⁇ and IL-8 in serum after intramuscular injection of the mRNA encoding uricase to rats.
  • SD rats aged 6 to 8 weeks (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) were raised under SPF conditions and kept in ventilated cages under 12h light and 12h dark cycles.
  • the mRNA encoding uricase was intramuscularly injected at a dose of 100 ⁇ g per rat, and the injection doses of the corresponding protein drugs Rasburicase and Pegloticase were both 500 ⁇ g/rat. After 24 hours, blood was collected from the orbit of the rats to separate the serum.
  • Enzyme-linked immunosorbent assay (ELISA) was performed with rat IL-8 and TNFa kit (RayBio).
  • Table 2 The levels of TNF ⁇ and IL8 after injection of mRNA and corresponding protein drugs in rats (unit: pg/ml)
  • Drug encoding uricase mRNA significantly reduces blood uric acid levels in rats
  • the therapeutic effect of the drug encoding uricase mRNA is detected, and the evaluation standard is the level of uric acid in serum after intravenous injection of uricase mRNA to rats.
  • the above uricase mRNA was injected intravenously into the rats, the injection dose of each rat was 200 ⁇ g, and the injection dose of the corresponding protein drugs Rasburicase and Pegioticase was 1 mg/rat, administered once a week, and after 4 weeks Blood was collected from the orbits of the rats, and the serum was separated.
  • Enzyme-linked immunosorbent assay (ELISA) was performed with rat uric acid detection kit.
  • Detect the bioavailability and half-life of the encoding uricase mRNA drug in rats and the evaluation standard is the change of uricase protein content in serum after intravenous injection of uricase mRNA and uricase protein to rats.
  • the drug for treating hyperuricemia, gout or renal function injury provided by the present invention has low immunogenicity and can significantly reduce the uric acid content.

Abstract

提供了一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物及其制备方法和应用，所述药物包括SEQ ID No.1和/或SEQ ID No.2所示的编码尿酸酶的mRNA。将编码尿酸酶的mRNA递送至体内，利用人体细胞表达尿酸酶，加快了血液中尿酸的代谢速度，显著降低了尿酸含量，从而起到治疗高尿酸血症和痛风的作用。所述治疗高尿酸血症的药物-编码尿酸酶的mRNA生物利用率高、半衰期长，免疫原性低、大大降低了过敏反应，提高了患者的用药依从性和安全性。

Description

一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物及其制备方法和应用
本发明要求于2021年06月25日提交中国专利局、申请号为202110707208.7、发明名称为“一种基于mRNA剂型的治疗高尿酸血症或痛风的药物及其制备方法”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明属于高尿酸血症或痛风的治疗技术领域，尤其涉及一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物及其制备方法和应用。
背景技术
高尿酸血症患者由于嘌呤代谢产生过量尿酸导致血液中尿酸含量升高，当血尿酸水平超过关节单钠尿酸盐饱和度而析出、沉积于外周关节及周围组织时则引起痛风。当尿液中的尿酸达到过饱和，肾小管和远端收集系统出现尿酸结晶会引起肾功能损伤。
目前高尿酸血症的标准预防或治疗方案为使用别嘌醇治疗，进行尿液碱化，水利尿和渗透性利尿。别嘌醇通过抑制黄嘌呤氧化酶阻滞尿酸形成，但会增加肾脏排泄尿酸前体(次黄嘌呤和黄嘌呤)的负荷。与次黄嘌呤不同，黄嘌呤在尿中比尿酸难溶。有时别嘌醇治疗的病人也可出现黄嘌呤肾病和结石。此外，对于病人体内存留的尿酸的排泄，使用别嘌醇治疗无效。
另一种治疗方法是使用蛋白类药物尿酸酶，尿酸酶药物的安全性较高，且未影响患者的肝肾功能，是治疗痛风的理想药物。尿酸酶的主要不良事件为输注反应，发生在多达40％的患者中；并且出现在尿酸降低起效之前，表现出恶心、皮肤潮红和呼吸困难的症状。大约40％多的患者存在高滴度的抗体，并且与治疗反应的丧失和输注反应的风险增加有关。部分使用该药的患者会出现严重的过敏反应，并且出现在使用该药的2h之内。
对于高尿酸症的治疗，目前没有一种有效、安全的药物。
发明内容
有鉴于此，本发明的目的在于提供一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物及其制备方法和应用；所述治疗高尿酸血症的药物为编码尿酸酶的mRNA，本发明将编码尿酸酶的mRNA递送至体内，利用人体细胞表达尿酸酶，加快了血液中尿酸的代谢速度，显著降低了尿酸含量，从而起到治疗高尿酸血症和痛风的作用。
本发明提供的治疗高尿酸血症的药物-编码尿酸酶的mRNA生物利用率高、半衰期长，免疫原性低、大大降低了过敏反应，提高了患者的用药依从性和安全性。
为了实现上述发明目的，本发明提供了以下技术方案：
本发明提供了一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物，包括SEQ ID No.1和/或SEQ ID No.2所示的编码尿酸酶的mRNA。
优选的，所述编码尿酸酶的mRNA的5’端连接5’UTR和帽子结构；所述编码尿酸酶的mRNA的3’端连接3’UTR和多聚A尾。
优选的，所述药物为液体制剂。
优选的，所述药物为注射制剂。
优选的，所述编码尿酸酶的mRNA在所述药物中的浓度为0.5～1.5μg/μl。
优选的，所述药物的溶剂为生理盐水。
本发明提供了所述的药物的制备方法，包括以下步骤：
1)合成转录所述编码尿酸酶的mRNA的DNA片段，将所述DNA片段克隆至表达质粒获得重组质粒；
2)将所述重组质粒转入宿主细胞获得重组细胞，从扩繁后的重组细胞中提取质粒，并以提取获得的质粒为模板进行PCR扩增获得体外表达mRNA的DNA模板；
3)构建包括所述DNA模板的RNA体外合成体系进行mRNA的体外合成，获得所述编码尿酸酶的mRNA。
优选的，所述RNA体外合成体系以1600μl计，包括以下组分：
Figure PCTCN2021103464-appb-000001
优选的，所述RNA体外合成的程序为36～38℃，5～7h。
优选的，步骤3)获得所述编码尿酸酶的mRNA后还包括：调节所述编码尿酸酶的mRNA浓度后分装。
本发明提供了所述的药物在治疗高尿酸血症、痛风或肾功能损伤中的应用。
优选的，所述药物的使用方法包括静脉注射。
本发明的有益效果：本发明提供的治疗高尿酸血症、痛风或肾功能损伤的药物为 编码尿酸酶的mRNA，本发明将编码尿酸酶的mRNA递送至体内，利用人体细胞表达尿酸酶，加快了血液中尿酸的代谢速度，显著降低了尿酸含量，从而起到治疗高尿酸血症、痛风以及由尿酸过多形成结晶引起的肾功能损伤的作用。
本发明提供的治疗高尿酸血症的药物-编码尿酸酶的mRNA生物利用率高、半衰期长，免疫原性低、大大降低了过敏反应，提高了患者的用药依从性和安全性。
根据实施例的记载，在大鼠体内注射本发明提供的编码尿酸酶的mRNA后，TNFα和IL-8的表达水平远低于注射相应的蛋白药物，说明本发明提供的编码尿酸酶的mRNA的免疫原性远远小于相应的蛋白药物。在大鼠体内注射相应的蛋白药物，大鼠尿酸水平降低不显著，注射本发明提供的编码尿酸酶的mRNA药物的大鼠体内尿酸水平显著下降，说明本发明提供的治疗高尿酸血症的药物治疗效果更好。
附图说明
图1为编码尿酸酶的mRNA的结构示意图；
图2为pRhe质粒的质粒图谱；
图3为编码尿酸酶的mRNA(Seq1和Seq2)转染细胞后36h蛋白表达水平；
图4为大鼠注射编码尿酸酶的mRNA及相应蛋白药物体内免疫因子水平检测，其中A为TNFα的表达水平，B为IL-8的表达水平；
图5为大鼠注射编码尿酸酶的mRNA及相应蛋白药物后血液中的尿酸水平；
图6为尿酸酶mRNA药物与蛋白药物生物利用率及半衰期对比，其中A为注射编码尿酸酶的mRNA(Seq1)和对应的蛋白药物后7d血液中尿酸水平，B为注射编码尿酸酶的mRNA(Seq2)和对应的蛋白药物后7d血液中尿酸水平。
具体实施方式
本发明提供了一种基于mRNA剂型的治疗高尿酸血症、痛风或肾功能损伤的药物，包括SEQ ID No.1和/或SEQ ID No.2所示的编码尿酸酶的mRNA；具体如下：
SEQ ID No.1(以下简称seq 1)：
Figure PCTCN2021103464-appb-000002
Figure PCTCN2021103464-appb-000003
SEQ ID No.2(以下简称seq 2)：
Figure PCTCN2021103464-appb-000004
在本发明中，所述编码尿酸酶的mRNA的5’端连接5’UTR和帽子结构；所述编码 尿酸酶的mRNA的3’端连接3’UTR和多聚A尾；具体结果如图1所示。
在本发明中，所述治疗高尿酸血症、痛风或肾功能损伤的药物优选为液体制剂，更优选为注射制剂。在本发明中，所述编码尿酸酶的mRNA在所述药物制剂中的浓度优选为0.5～1.5μg/μl，更优选为1μg/μl。所述编码尿酸酶的mRNA的溶剂优选为生理盐水。本发明对所述生理盐水的制备方法没有特殊限定，采用本领域常规的生理盐水即可。本发明对所述注射制剂的制备方法没有特殊限定，满足本领域常规注射制剂的要求即可。
本发明还提供了所述的药物的制备方法，包括以下步骤：1)合成转录所述编码尿酸酶的mRNA的DNA片段，将所述DNA片段克隆至表达质粒获得重组质粒；2)将所述重组质粒转入宿主细胞获得重组细胞，从扩繁后的重组细胞中提取质粒，并以提取获得的质粒为模板进行PCR扩增获得体外表达mRNA的DNA模板；3)构建包括所述DNA模板的RNA体外合成体系进行mRNA的体外合成，获得所述编码尿酸酶的mRNA。
在本发明中，合成转录所述编码尿酸酶的mRNA的DNA片段，并将所述DNA片段克隆至表达质粒获得重组质粒。本发明对合成所述编码尿酸酶的mRNA对应的DNA片段的方法没有特殊限定，采用本领域常规的DNA合成方法即可，在本发明具体实施过程中，优选的委托生物技术公司合成。在本发明中，所述DNA片段的具体序列根据碱基互补配对原则确定。在本发明中，所述表达质粒优选为pRhe质粒，在本发明中，所述pRhe质粒的质粒图谱如图2所示。在本发明中，优选的通过酶切连接的方法将所述DNA片段克隆至表达质粒中；在本发明中，所述DNA片段优选的通过BamHI和NheI酶进行双酶切获得酶切NDA片段；所述表达质粒优选的通过BamHI和NheI酶进行双酶切后获得酶切质粒；然后将所述酶切DNA片段和酶切质粒连接获得重组质粒。本发明对所述双酶切和连接的具体操作没有特殊限定，采用本领域常规的双酶切和连接的操作即可。
本发明在获得所述重组质粒后，将所述重组质粒转入宿主细胞获得重组细胞，从扩繁后的重组细胞中提取质粒，并以提取获得的质粒为模板进行PCR扩增获得体外表达mRNA的DNA模板。在本发明中，所述宿主细胞优选为大肠杆菌感受态细胞；本发明对所述转入的方法没有特殊限定，采用本领域常规的转入方法即可。本发明在获得重组细胞后，优选的进行阳性重组细胞的筛选和菌落测序。在本发明中，所述阳性重组细胞的筛选优选的在amp抗性的固体培养基上进行。在本发明中，挑选所述amp抗性的固体培养基上的单菌落培养后的菌液进行菌落PCR，选取菌落PCR结果含目的条带的菌落进行测序。在本发明中，所述菌落PCR的引物F序列如下： CTCTAGAGGATCGAACCCTT(SEQ ID No.3)；所述菌落PCR的引物R的序列如下：AAACCCGCTGATCAGCCTCG(SEQ ID No.4)。在本发明中，所述菌落PCR的扩增程序优选的如下：预变性98℃3min；变性98℃10s，退火60℃5s，延伸72℃2min，34个循环；最后延伸72℃，10min。在本发明中，所述菌落PCR的体系优选的如下：
Figure PCTCN2021103464-appb-000005
在本发明中，所述引物F和引物R的初始浓度优选为10μmol/L，所述DNA模板的浓度优选为1ng/μl。本发明在所述PCR扩增结束后，优选的通过琼脂糖凝胶电泳确定含目的条带的菌落，然后进行测序验证。
在本发明中，提取测序正确的重组细胞的质粒；本发明对所述质粒的提取方法没有特殊限定，优选的采用质粒提取试剂盒进行。在本发明中，以提取获得的质粒为模板进行PCR扩增获得体外表达mRNA的DNA模板。在本发明中，所述PCR扩增的体系以50μl计，优选的如下：
Figure PCTCN2021103464-appb-000006
在本发明中，所述引物F和引物R的初始浓度优选为10μmol/L；所述DNA模板的浓度优选为1ng/μl。在本发明中，所述引物F的序列如下：CTCTAGAGGATCGAACCCTT(SEQ ID No.3)；所述引物R的序列如下：AAACCCGCTGATCAGCCTCG(SEQ ID No.4)。在本发明中，所述PrimeSTAR Max Premix(2×)包括以下组分：PrimeSTAR Max DNA Polymerase，dNTPs和Mg 2+。在本发明中，所述PCR的扩增程序优选的如下：预变性98℃3min；变性98℃10s，退火60℃5s，延伸72℃2min，34个循环；最后延伸72℃，10min。
在本发明中，所述PCR扩增反应结束后，优选的对扩增产物进行琼脂糖凝胶电泳检测以确定反应是否成功；所述琼脂糖凝胶电泳检测的参数优选的如下：1.5％琼脂糖，5V/min，40min。在本发明中，当琼脂糖凝胶电泳出现目的条带认为反应成功。
本发明在所述PCR扩增反应结束后，优选的将所述扩增产物进行浓缩和纯化。在 本发明中，所述浓缩优选的采用Millipore 30Kd超滤管进行；所述纯化优选的采用FPLC进行；本发明在所述纯化后优选的采用NanoDrop检测纯化后模板的浓度，以及260/280、当260/280在1.6～1.8之间，认为模板合格。
本发明在获得所述DNA模板后，构建包括所述DNA模板的RNA体外合成体系进行mRNA的体外合成获得所述活性成分mRNA。在本发明中，所述RNA体外合成体系以1600μl计，包括以下组分：
Figure PCTCN2021103464-appb-000007
在本发明中，所述Enzyme Mix包括T7RNA聚合酶，RNA酶抑制剂和无机焦磷酸酶。在本发明中，所述RNA体外合成的程序优选的为36～38℃、5～7h，更优选为37℃、6h。在本发明中，所述RNA体外合成优选的在恒温反应器中进行；所述RNA体外合成体系优选的置于2ml RNase-free Tube管中，一次同时反应多管；所述RNA体外合成体系中的反应试剂按照上述组分顺序添加。
本发明在所述RNA体外合成结束后，优选的还包括去除DNA模板、回收mRNA和纯化mRNA的步骤。在本发明中，所述去除DNA模板优选的通过DNase I消化实现；所述消化优选的包括将DNase I与RNA体外合成反应后的溶液混合后进行；所述DNase I与RNA体外合成反应后的溶液的体积比优选为3:40；所述混合优选的通过上下颠倒所述RNase-free Tube管实现，所述上下颠倒的次数优选为8～12次，更优选为10次。本发明在所述混合后，优选的进行离心将溶液收集至RNase-free Tube管底部。在本发明中，所述离心的转速优选为800～1200rpm，更优选为1000rpm；所述离心的时间优选为8～12s，更优选为10s。所述消化的温度优选为37℃；所述消化的时间优选为1h。本发明在所述消化结束后，优选的进行DNA片段残留检测。在本发明中，所述回收mRNA优选的通过醋酸铵溶液沉淀实现；具体实施方法参见实施例记载。本发明在回收mRNA后，进行mRNA的质量检测；所述质量检测包括mRNA的浓度、mRNA的260/280、260/230的比值。当260/280范围为1.8～2.1，260/230范围为大于2.0时，认为mRNA 合格。在本发明中，所述纯化mRNA通过FPLC纯化实现。本发明所述纯化mRNA后，优选的对纯化后的mRNA进行分装。
下面结合实施例对本发明提供的技术方案进行详细的说明，但是不能把它们理解为对本发明保护范围的限定。
实施例1
重组质粒制备：
1)合成编码seq1、seq2的目的DNA片段；
2)将目的片段和pRhe质粒分别进行BamHI和NheI双酶切，
3)使用T4连接酶进行体外连接；
4)转化大肠杆菌感受态，在amp固体培养基上培养12h；
5)菌落PCR，选取含目的条带的菌落进行测序。
6)测序正确的菌落扩大培养，质粒提取。
菌落PCR步骤如下：
单菌落挑取：
把LB培养基倒入排枪槽中，然后用排枪加400μl LB培养基到48孔深孔板，用镊子拿已灭菌的小白枪头挑取平板上的单菌落并放到48孔深孔板中，同时在48孔深孔板和相应的表单上做好记录。挑好的48孔深孔板用封口膜盖好并做好相应标记(日期、板号等)，用针头在封口膜打孔，把它放在37℃摇床上摇1h。
菌落PCR反应：
配制好如下PCR反应体系，把配好的反应液加到96孔板中，用排枪加2μl菌液到其中，按照PCR程序进行扩增：
Figure PCTCN2021103464-appb-000008
在本发明中，所述引物F和引物R的初始浓度为10μmol/L；所述DNA模板的浓度为1ng/μl。在本发明中，所述引物F的序列如下：CTCTAGAGGATCGAACCCTT(SEQ ID No.3)；所述引物R的序列如下：AAACCCGCTGATCAGCCTCG(SEQ ID No.4)。在本发明中，所述PCR的扩增程序优选的如下：预变性98℃3min；变性98℃10s，退火60℃5s，延伸72℃2min，34个循环；最后延伸72℃，10min。
琼脂糖凝胶电泳：
先配制1％琼脂糖凝胶(称取1g琼脂糖加入100ml的TAE溶液中)，在完成PCR反应的96孔板中加入0.5μl溴酚蓝，震荡混匀，然后点样，电泳好的琼脂糖凝胶拍照、保存。
判断阳性克隆并测序：
根据琼脂糖凝胶电泳条带图来判断阳性克隆，把阳性克隆的菌液进行扩大培养，进行测序验证，选取具备完全正确序列的克隆进行下一步操作。
质粒提取的步骤参见omega D6915 Endo-free Plasmid Midi Kit说明书。
得到的质粒按如下反应体系进行DNA模板的扩增：
反应体积，50μl(为单个管的反应体积，一次同时反应多管)
所述PCR扩增的体系以50μl计，优选的如下：
Figure PCTCN2021103464-appb-000009
PrimeSTAR Max Premix(2×)包括以下组分：PrimeSTAR Max DNA Polymerase，dNTPs和Mg 2+。引物F和引物R的初始浓度优选为10μmol/L；所述DNA模板的浓度优选为1ng/μl。所述引物F的序列如下：CTCTAGAGGATCGAACCCTT(SEQ ID No.3)；所述引物R的序列如下：AAACCCGCTGATCAGCCTCG(SEQ ID No.4)。所述PCR的扩增程序如下：预变性98℃3min；变性98℃10s，退火60℃5s，延伸72℃2min，34个循环；最后延伸72℃，10min。
反应结束后，将反应液合并于1.5ml Tube管中。取10μl进行DNA琼脂糖凝胶电泳检测以确定反应成功(1.5％琼脂糖，5V/min，40min)。
合格标准：电泳检测出现单一的条带，且大小正确。
测定结果：条带单一，大小符合要求。
DNA模板超滤
利用Millipore 30Kd超滤管浓缩上述获得的DNA模板。
DNA模板的纯化
将上述超滤得到的DNA，加入等体积的苯酚/氯仿/异戊醇混合液(苯酚/氯仿/异戊醇＝25/24/1)，充分震荡后，12000g离心15min。
去掉沉淀，转移上清至新的离心管中，加入上清体积1/10的3M NaAc(PH5.2)，混匀，然后加入2倍体积的无水乙醇，混匀，至于-20℃静至30min。
4℃，12000g离心10min，弃上清。
用体积百分含量为70％乙醇洗涤沉淀，12000g离心5min，取上清，于超净台晾干5min。
用适当的RNase-free水溶解纯化后的DNA模板。
用NanoDrop检测纯化后模板的浓度，以及260/280、260/230的比值。取样进行DNA琼脂糖凝胶电泳检测(1.5％琼脂糖，5V/min，40min)。
合格标准：260/280介于1.8至2.1之间，260/230在1.6至2.2之间。
测定结果：浓度为500ng/μl，260/280＝1.90，260/230＝1.7。
纯化后模板超滤
Millipore 30Kd超滤管浓缩FPLC纯化后的DNA模板，用RNase-free水洗脱溶解。用NanoDrop检测超滤后模板的浓度，以及260/280、260/230的比值。最终用RNase-free水稀释至150ng/μl。
测定结果：浓度为150ng/μl，260/280＝1.95，260/230＝1.85。
mRNA的体外合成
在恒温反应器中，进行mRNA的体外合成。
按照如下合成体系进行(反应试剂按照从上至下添加)：
反应体积，1600μl(置于2ml RNase-free Tube管中，为单个管的反应体积，一次同时反应多管)。
所述RNA体外合成体系以1600μl计，包括以下组分：
Figure PCTCN2021103464-appb-000010
所述RNA体外合成的程序为37℃，6h。
DNase I消化去除DNA模板
向mRNA体外合成后的每个Tube管中各加入120μl DNase I。
上下颠倒10次混匀，1000rpm离心10s。
重新置于恒温反应器中，37℃，1h。
反应结束后，将反应液合并到RNase-free 50ml Tube管中，检测DNA片段的残留，三次测量结果DNA片段残留分别为0.013ng，0.016ng，0.017ng每100μg mRNA。
DNA残留检测的方法：
采用定量实时PCR检测方法，具体操作步骤如下：
(1)供试品溶液配制：取样品适量，用无酶水稀释10倍，混匀，混得。
(2)标准品溶液配制：用无酶水将标定过的质粒标准品进行稀释至1E+08copies/μl，然后再进行梯度稀释。具体操作如下：
Figure PCTCN2021103464-appb-000011
ERC的制备：取20μl供试品溶液，加入20μl ST4，混匀，即得。
MIX反应液配制：以SuperFast Probe Mixtuure：W2306F：W2521R：W2430P：H 2O＝10：0.6:0.6:0.4:7.4的比例进行配制，混匀，即得。
PCR管加样：每孔加入19μl qPCR MIX、再依次加入1μl标准曲线(ST1/ST2/ST3/ST4/ST5/ST6)、ERC、NTC、供试品溶液，混匀。每个样各做三个平行。
PCR程序设定如下：
Figure PCTCN2021103464-appb-000012
计算公式：以标准品的Ct值对其浓度的对数值做图，线性回归分析，将样品Ct值代入方程，计算“稀释10倍后的浓度对数的检测值”，计算“DNA残留”。
DNA残留浓度(copies/μl)＝检测值×稀释倍数
Figure PCTCN2021103464-appb-000013
结果判定：三个平行孔间的Ct差值应小于1.0；Ct值大于35的样本除外。
线性相关系数R 2>0.99。
无模板对照NTC应不得检出或大于标准曲线最低浓度2个Ct值。
标准规定：应不高于1ng/μl。
mRNA沉淀回收
向上一步骤中的每个50ml Tube管中，加入等体积的醋酸铵溶液。
上下颠倒10次混匀。
置于-20℃2h，沉淀。
17000g，4℃离心，30min。
去掉上清，用体积百分含量为70％乙醇洗涤沉淀。
17000g，4℃离心，10min。
去掉70％乙醇，于超净台中蒸干，每管加入RNase-free水20ml。
静置10min后，用枪头轻吹混匀。
用NanoDrop检测回收后的mRNA浓度为5μg/μl，A260/A280为1.90、A260/A230为2.0。
取1μl，稀释10倍，进行RNA ScreenTape assay以及琼脂糖凝胶电泳检测其片段完整性。
检测结果：条带符合大小，片段完整。
LiCl沉淀纯化mRNA
将上一步骤中回收的mRNA按照其1.5倍体积加入Rnase-free水，混匀。
加入原mRNA 1.5倍体积-20℃预冷的LiCl溶液，混匀。
然后于-20℃静置2h。
16000g离心20min。
弃上清，用70％乙醇洗涤沉淀，16000g离心15min。
取上清，于超净台晾干5min。
用适当的RNase-free水溶解纯化后的mRNA。
纯化后的mRNA浓度为2μg/μl，A260/A280为1.95、A260/A230为1.9。
mRNA分装
将上一步骤中纯化后的mRNA分装至西林瓶。
实施例2
编码尿酸酶的mRNA表达水平检测
实验方法：体外效力-Western Blot检测
1)细胞准备：提前3天准备检测用细胞。取购自中科院细胞库的293T细胞，传代于细胞培养瓶内，保证使用时细胞处于对数生长期。
2)细胞消化计数：取生长状态良好的293T细胞，去掉培养基，以10ml PBS清洗细胞后，加入体积百分含量为0.25％胰酶(T75瓶加1ml 0.25％胰酶，T175瓶加3ml 0.25％胰酶)消化5min，然后加入含10％FBS的DMEM培养基(T75瓶用9ml培养基，T175瓶用17ml培养基)中和胰酶，吹打细胞并转至50ml离心管，反复吹打混匀，然后取0.3～0.5ml的细胞悬液，计数。
3)细胞稀释：取1ml细胞悬液，用含10％FBS的DMEM培养基稀释到5×10 5个/ml，吹打混匀。
4)细胞接种：取2ml细胞悬液加到6孔板内。每个mRNA样品需要准备2孔平行细胞，对照组样品(GFP-mRNA)需要准备1孔细胞，空白对照1孔。将6孔板放入(37±1)℃、(5±0.5)％CO 2培养箱培养过夜。
细胞转染
接种完细胞后24h，观察6孔板内的细胞状态，汇合度在90％左右。在生物安全柜内，配制所需体积的90％DMEM+10％FBS培养基。转染前30min弃掉孔板的培养基，每孔加入1ml新鲜培养基(90％DMEM+10％FBS)。
a)配制转染体系：取200μl opti-MEM，加入10μg mRNA样品(SEQ ID No.1、SEQ ID No.2)或阴性对照GFP-mRNA，用枪头轻轻吹打混匀，再加入60μl PEI(浓度1mg/ml)，立即置于漩涡振荡器上振荡10次，每次1s，充分混匀，静置10min。
b)将配制好的转染体系，直接均匀滴加进入培养的细胞中，再前后左右摇匀，使得转染体系均匀分布于细胞上。
c)换液
转染后6h换液，吸掉旧的培养基，每孔换为2ml新鲜培养基(90％DMEM+10％FBS)。
d)收获
转染后30h收获。吸掉旧的培养基，用1ml PBS清洗一遍。
吸掉PBS，继续用1ml PBS将细胞吹打下来，收集于1.5ml离心管中，300g离心5min。将离心后的上清尽量吸去干净，沉淀的细胞用于Western blot检测。
免疫酶联吸附检测
实验步骤：
1.包被：包被的标准品浓度为0.1μg/μl，0.01μg/μl，0.001μg/μl，0.0001μg/μl，0.00001μg/μl，0.000001μg/μl，稀释于coating buffer，体积为100μl。包被的细胞裂解液 体积为100μl，排枪加至96孔板，盖上封板膜，4℃过夜包被。标准品为mRNA seq1、mRNA seq2所编码的重组蛋白Rasburicase和Pegloticase。
2.封闭：包被好的96孔板，倒出包被液，到扣吸水纸上，使劲扣板，直到孔中无残留为止。
3.洗板：配制洗脱液，用去离子水稀释50x的Washing buffer，加入到洗板机的进液瓶中，设置程序，每孔洗板体积设为300μl，重复洗4次。
4.封闭：洗好的板，扣干里面的溶液，按每孔250μl的体积加入Blocking buffer，随后封上封板膜，室温封闭2h。
5.洗板：封闭好的酶标板按照步骤3完成洗板。
6.一抗孵育：用dilution buffer稀释一抗(1：1000)，按照每孔100μl的体积加入洗好的96孔板中，随后封上封板膜室温下孵育1.5h。
7.洗板：按照步骤3完成洗板，洗板次数增加为6次。
8.加入二抗：用Dilution buffer稀释HRP标记二抗IgG，稀释倍数为10000x，稀释好的抗体按照每孔100μl的体积加入酶标板中，封上封板膜，室温下避光孵育1h。
9.洗板：按照步骤8完成洗板，此步骤务必洗干净板，扣干溶液。
10.显色：加入TMB buffer 100μl，避光显色25min，此时阳性样品显蓝色。
11.终止：加入Stop buffer 100μl，10min内在酶标板上读数，设置吸收波长450nm。
编码尿酸酶的mRNA(Seq1和Seq2)分别转染细胞后30h蛋白表达水平如图3和表1所示，seq1 mRNA和seq2具备体外生物活性，在细胞内能够表达出正确的蛋白产物，seq1 mRNA的表达强度平均值为38.2pg/ml，Seq2 mRNA的表达强度平均值为75.1pg/ml。
表1编码尿酸酶的mRNA细胞表达水平检测(单位：pg/ml)
  Control GFP mRNA Seq1 mRNA Seq2 mRNA
1 0 0 41.6 77.2
2 0 0 39.2 68.3
3 0 0 33.8 79.8
平均值 - - 38.2 75.1
实施例2
检测本发明提供的编码尿酸酶的mRNA的免疫原性，评价标准为对大鼠进行肌肉注射编码尿酸酶的mRNA后血清中TNFα和IL-8的表达水平。
将6～8周龄的SD大鼠(购买自北京维通利华实验动物技术有限公司)，饲养在SPF条件下，并且保持12h光亮和12h黑暗循环下的通气笼中饲养，对大鼠进行肌肉注射编码 尿酸酶的mRNA，每只大鼠的注射剂量为100μg，相应蛋白药物Rasburicase和Pegloticase的注射剂量均为500μg/只，24h后对大鼠进行眼眶取血，分离血清。用大鼠IL-8和TNFa试剂盒(RayBio)进行酶联免疫吸附分析检测(ELISA)。
结果如图4和表2所示，在大鼠体内，本发明提供的编码尿酸酶的mRNA的免疫原性远远小于相应的蛋白药物Rasburicase和Pegloticase。
表2大鼠注射mRNA及相应蛋白药物后TNFα及IL8水平(单位：pg/ml)
  对照 GFP mRNA Seq 1 mRNA Seq 2 mRNA Rasburicase Pegioticase
TNFα 46.5 64.3 102.1 88.2 378.4 355.7
IL8 41.0 78.2 53.8 60.6 335.7 364.2
实施例3
编码尿酸酶mRNA的药物显著降低大鼠血液尿酸水平
检测所述编码尿酸酶的mRNA的药物的治疗效果，评价标准为编码尿酸酶的mRNA对大鼠进行静脉注射后血清中尿酸水平。
体重约200g成年雄性SD大鼠(购买自北京维通利华实验动物技术有限公司)，饲养在SPF条件下，并且保持12h光亮和12h黑暗循环下的通气笼中饲养，分别以200mg/kg体重的剂量给大鼠灌服腺嘌呤加乙胺丁醇，每天灌服1次，共14天，使血尿酸水平升高，自喂食高腺嘌呤和乙胺丁醇食物一周后，开始检测大鼠血液中的尿酸水平，结果显示大鼠血尿酸水平升高一倍以上，确认造模成功。造模结束后将以上尿酸酶mRNA对大鼠进行静脉注射，每只大鼠的注射剂量为200μg，相应蛋白药物Rasburicase和Pegioticase的注射剂量为1mg/只，每周给药1次，4周后对大鼠进行眼眶取血，分离血清。用大鼠尿酸检测试剂盒进行酶联免疫吸附分析检测(ELISA)。
结果如图5和表3所示，注射蛋白药物的大鼠尿酸水平变化不明显，注射编码尿酸酶的mRNA药物的大鼠体内尿酸水平显著下降。
表3编码尿酸酶的mRNA注射后血液中尿酸水平(单位：mmol/L)
  对照 GFP mRNA Seq 1 mRNA Seq 2 mRNA Rasburicase Pegioticase
1 94.1 89.6 30.2 27.9 81.9 70.7
2 87.8 92.3 37.1 27 80.8 67.8
3 107.6 110.3 31.9 18.6 64.1 65.2
平均值 96.5 97.4 33.2 24.5 75.6 67.9
实施例4
尿酸酶mRNA药物与蛋白药物生物利用率及半衰期对比
检测所述编码尿酸酶mRNA药物在大鼠体内的生物利用率和半衰期，评价标准为 编码尿酸酶的mRNA及尿酸酶蛋白对大鼠进行静脉注射后血清中尿酸酶蛋白含量变化。
体重约200g成年雄性SD大鼠(购买自北京维通利华实验动物技术有限公司)，饲养在SPF条件下，并且保持12h光亮和12h黑暗循环下的通气笼中饲养，mRNA注射剂量为200μg/只，相应蛋白药物Rasburicase和Pegioticase的注射剂量为1mg/只，每天对大鼠进行眼眶取血，分离血清，通过酶联免疫吸附分析检测(ELISA)血清中相应蛋白质的含量。
结果如图6和表4所示，注射蛋白药物的大鼠尿酸酶水平迅速下降，注射编码尿酸酶的mRNA药物的大鼠体内尿酸酶水平维持高水平。
表4编码尿酸酶的mRNA及相应蛋白药物注射后血液中尿酸酶u水平(单位：ng/μL)
  Seq 1 mRNA Seq 2 mRNA Rasburicase Pegioticase
1 222.7 289 51 58
2 326 360 26.7 21
3 257 307 13.4 16
4 167 232 2 4
5 66 98 0 0
6 49 49 0 0
7 17 20.5 0 0
由上述实施例可知，本发明提供的治疗高尿酸血症、痛风或肾功能损伤的药物免疫原性低、能够显著降低了尿酸含量。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。

Claims (12)

  1. 一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物，其特征在于，包括SEQ ID No.1和/或SEQ ID No.2所示的编码尿酸酶的mRNA。
  2. 根据权利要求1所述的药物，其特征在于，所述编码尿酸酶的mRNA的5’端连接5’UTR和帽子结构；所述编码尿酸酶的mRNA的3’端连接3’UTR和多聚A尾。
  3. 根据权利要求1所述的药物，其特征在于，所述药物为液体制剂。
  4. 根据权利要求3所述的药物，其特征在于，所述药物为注射制剂。
  5. 根据权利要求3或4所述的药物，其特征在于，所述编码尿酸酶的mRNA在所述药物中的浓度为0.5～1.5μg/μl。
  6. 根据权利要求3或4所述的药物，其特征在于，所述药物的溶剂为生理盐水。
  7. 权利要求1～6任意一项所述的药物的制备方法，包括以下步骤：
    1)合成转录权利要求1所述药物中编码尿酸酶的mRNA的DNA片段，将所述DNA片段克隆至表达质粒获得重组质粒；
    2)将所述重组质粒转入宿主细胞获得重组细胞，从扩繁后的重组细胞中提取质粒，以提取获得的质粒为模板进行PCR扩增获得体外表达mRNA的DNA模板；
    3)构建包括所述DNA模板的RNA体外合成体系进行mRNA体外合成，获得所述编码尿酸酶的mRNA。
  8. 根据权利要求7所述的制备方法，其特征在于，所述RNA体外合成体系以1600μl计，包括以下组分：
    Figure PCTCN2021103464-appb-100001
  9. 根据权利要求7或8所述的制备方法，其特征在于，所述RNA体外合成的程序 为36～38℃，5～7h。
  10. 根据权利要求7所述的制备方法，其特征在于，步骤3)获得所述编码尿酸酶的mRNA后还包括：调节所述编码尿酸酶的mRNA浓度后分装。
  11. 权利要求1～6任意一项所述的药物在治疗高尿酸血症、痛风或肾功能损伤中的应用。
  12. 根据权利要求11所述的应用，其特征在于，所述药物的使用方法包括静脉注射。
PCT/CN2021/103464 2021-06-25 2021-06-30 一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物及其制备方法和应用 WO2022267086A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110707208.7 2021-06-25
CN202110707208.7A CN113244412B (zh) 2021-06-25 2021-06-25 一种基于mRNA剂型的治疗高尿酸血症或痛风的药物及其制备方法

Publications (1)

Publication Number Publication Date
WO2022267086A1 true WO2022267086A1 (zh) 2022-12-29

Family

ID=77189678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/103464 WO2022267086A1 (zh) 2021-06-25 2021-06-30 一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN113244412B (zh)
WO (1) WO2022267086A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056713B1 (en) * 1998-08-06 2006-06-06 Duke University Urate oxidase
CN108103079A (zh) * 2017-06-20 2018-06-01 北京五加和分子医学研究所有限公司 一种高尿酸血症的基因治疗药物
CN111088268A (zh) * 2019-03-05 2020-05-01 北京五加和分子医学研究所有限公司 一种高尿酸血症的基因治疗药物
CN111909906A (zh) * 2019-05-10 2020-11-10 重庆派金生物科技有限公司 聚乙二醇修饰的尿酸氧化酶

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2435847C2 (ru) * 2005-04-11 2011-12-10 Савиент Фармасьютикалз, Инк. Вариантная форма урат-оксидазы и ее использование
CN101003794B (zh) * 2007-01-11 2010-05-19 厦门大学 人pex外泌型重组腺病毒的构建方法和应用
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN111744019B (zh) * 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056713B1 (en) * 1998-08-06 2006-06-06 Duke University Urate oxidase
CN108103079A (zh) * 2017-06-20 2018-06-01 北京五加和分子医学研究所有限公司 一种高尿酸血症的基因治疗药物
CN111088268A (zh) * 2019-03-05 2020-05-01 北京五加和分子医学研究所有限公司 一种高尿酸血症的基因治疗药物
CN111909906A (zh) * 2019-05-10 2020-11-10 重庆派金生物科技有限公司 聚乙二醇修饰的尿酸氧化酶

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PROTEIN 11 January 2011 (2011-01-11), ANONYMOUS : "secreted mammalian urate oxidase precursor [Mammalian expression vector pCK65]", XP093016179, retrieved from NCBI Database accession no. ADV16000.1 *
KEMMER, C. ET AL.: "Self-sufficient control of urate homeostatsis in mice by a synthetic circuit", NATURE BIOTECHNOLOGY, vol. 28, no. 4, 28 March 2010 (2010-03-28), XP009137044, ISSN: 1087-0156, DOI: 10.1038/nbt.1617 *
SAHIN, U. ET AL.: "mRNA-based therapeutics—developing a new class of drugs", NATURE REVIEWS DRUG DISCOVERY, vol. 13, 19 September 2014 (2014-09-19), XP037134862, ISSN: 1474-1776, DOI: 10.1038/nrd4278 *

Also Published As

Publication number Publication date
CN113244412B (zh) 2021-10-26
CN113244412A (zh) 2021-08-13

Similar Documents

Publication Publication Date Title
CN109666685B (zh) Hpv卵黄抗体及其在制备治疗hpv感染的药物的应用
CN113249380B (zh) 靶向covid-19新冠病毒的反义寡核苷酸、natac嵌合分子及其应用
EA024878B1 (ru) Ген, кодирующий мутантную глюкокиназу человека, отличающуюся увеличенной стабильностью, и его применение для контроля глюкозы в крови или предупреждения и лечения нарушений углеводного обмена
CN112353939B (zh) Gtpbp4蛋白作为免疫抑制剂的应用及敲低或过表达gtpbp4细胞系的构建
CN105950541A (zh) 一种hFGF21基因敲除人肝细胞株的构建方法
WO2023272568A1 (zh) 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用
CN115927473A (zh) 一种用于单纯疱疹病毒感染性疾病的基因治疗药物
CN111793721B (zh) eEF1D蛋白在制备预防或治疗口蹄疫病毒感染药物中的应用
WO2022267086A1 (zh) 一种治疗高尿酸血症、痛风或肾功能损伤的mRNA剂型的药物及其制备方法和应用
CN115141273B (zh) 一种猫杯状病毒的单克隆抗体及其应用
CN113425855B (zh) 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用
CN115161321B (zh) ssc-miR-30c-3p在制备抗PDCoV增殖药物中的应用
WO2022120936A1 (zh) 一种修饰的核酸及其应用
CN114632155A (zh) PKA抑制剂H89及其siRNA在制备治疗新型冠状病毒病药物中的应用
CN116716302B (zh) 一种用于降低食管癌细胞中nek2基因表达的核酸分子
CN110904056A (zh) 一种传染性支气管炎病毒rH120-YZS1Δ5a及其构建方法和应用
CN114480309B (zh) 抑制ALKBH1表达的shRNA慢病毒及其制备和应用
CN114507677B (zh) Ndufs1基因在治疗心梗后心衰中的应用和相关产品
CN110938627B (zh) Esco2抑制剂在制备用于治疗下咽癌的药物中的用途
CN116574798A (zh) piR-mmu-57256903在制备防治抗癌药物所致心脏疾病的药物中的应用
CN117398403A (zh) Lmo7抑制剂在制备治疗胶质瘤产品中的用途
TR2021009961A2 (tr) Sars cov-2 vi̇rüsüne karşi tamamen sivi bi̇r çoklu anti̇jen adjuvan bazli aşi üreti̇m prosesi̇
CN111575316A (zh) hKLK1重组质粒、高表达hKLK1的慢病毒颗粒及其构建方法和应用
CN117243977A (zh) 异恶唑-9联合间充质干细胞在制备预防或治疗急性肺损伤药物中的用途
CN115851836A (zh) pAAV-HBVp/HBV1.2重组载体及其构建方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21946575

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE